Share on StockTwits

AstraZeneca plc (LON:AZN)‘s stock had its “underweight” rating restated by equities researchers at JPMorgan Chase & Co. in a research report issued on Friday. They currently have a GBX 3,700 ($62.26) price target on the stock. JPMorgan Chase & Co.’s price objective points to a potential downside of 11.67% from the company’s current price.

Shares of AstraZeneca plc (LON:AZN) opened at 4127.00 on Friday. AstraZeneca plc has a 1-year low of GBX 3086.50 and a 1-year high of GBX 5750.00. The stock has a 50-day moving average of GBX 4367.54 and a 200-day moving average of GBX 4188.18. The company’s market cap is £52.124 billion.

Other equities research analysts have also recently issued reports about the stock. Analysts at Swedbank reiterated a “reduce” rating on shares of AstraZeneca plc in a research note on Monday. They now have a GBX 3,721.79 ($62.62) price target on the stock. Separately, analysts at Barclays reiterated an “equal weight” rating on shares of AstraZeneca plc in a research note on Monday. They now have a GBX 4,100 ($68.99) price target on the stock. Finally, analysts at Societe Generale reiterated a “sell” rating on shares of AstraZeneca plc in a research note on Friday, August 1st. They now have a GBX 3,740 ($62.93) price target on the stock. Six analysts have rated the stock with a sell rating, seventeen have issued a hold rating and six have assigned a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of GBX 4,068.68 ($68.46).

AstraZeneca PLC (LON:AZN) is a global biopharmaceutical company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.